BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22173428)

  • 1. Belatacept (Nulojix) for prevention of renal transplant rejection.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):98-9. PubMed ID: 22173428
    [No Abstract]   [Full Text] [Related]  

  • 2. Belatacept.
    Vincenti F; Dritselis A; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Aug; 10(9):655-6. PubMed ID: 21878974
    [No Abstract]   [Full Text] [Related]  

  • 3. Belatacept: a new biologic and its role in kidney transplantation.
    Su VC; Harrison J; Rogers C; Ensom MH
    Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belatacept: a new era of immunosuppression?
    El-Charabaty E; Geara AS; Ting C; El-Sayegh S; Azzi J
    Expert Rev Clin Immunol; 2012 Aug; 8(6):527-36. PubMed ID: 22992146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney transplant drug approved.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(15):1372. PubMed ID: 21785016
    [No Abstract]   [Full Text] [Related]  

  • 6. Belatacept: in adult kidney transplant recipients.
    Garnock-Jones KP
    BioDrugs; 2012 Dec; 26(6):413-24. PubMed ID: 22928660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept utilization recommendations: an expert position.
    Grinyó JM; Budde K; Citterio F; Charpentier B
    Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
    Charpentier B
    Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for using belatacept in combination with sirolimus.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk.
    Bestard O; Campistol JM; Morales JM; Sánchez-Fructuoso A; Cabello M; Cabello V; Pallardó LM; Grinyó JM
    Nefrologia; 2012 May; 32(3):374-84. PubMed ID: 22535159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological agents in kidney transplantation: belatacept is entering the field.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.
    Martin ST; Tichy EM; Gabardi S
    Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costimulation targeting therapies in organ transplantation.
    Gandhi AM; Fazli U; Rodina V; Qazi YA
    Curr Opin Organ Transplant; 2008 Dec; 13(6):622-6. PubMed ID: 19060553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation.
    Gupta G; Womer KL
    Drug Des Devel Ther; 2010 Dec; 4():375-82. PubMed ID: 21151624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summary of the US FDA approval of belatacept.
    Archdeacon P; Dixon C; Belen O; Albrecht R; Meyer J
    Am J Transplant; 2012 Mar; 12(3):554-62. PubMed ID: 22335273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belatacept in kidney transplantation.
    Wojciechowski D; Vincenti F
    Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
    Martin ST; Powell JT; Patel M; Tsapepas D
    Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Belatacept, a new original molecule, immunosuppressive, in organ transplantation].
    Beaudreuil S; Durrbach A; Kriaa F; Charpentier B
    Med Sci (Paris); 2006 Apr; 22(4):354-5. PubMed ID: 16597399
    [No Abstract]   [Full Text] [Related]  

  • 19. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.
    Grimbert P; Audard V; Diet C; Matignon M; Plonquet A; Mansour H; Desvaux D; Durrbach A; Cohen JL; Lang P
    Nephrol Dial Transplant; 2011 Mar; 26(3):1087-93. PubMed ID: 20667993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belatacept.
    Prescrire Int; 2012 Jul; 21(129):173-6. PubMed ID: 22852277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.